Cost-effectiveness of adjuvanted versus nonadjuvanted influenza vaccine in adult hemodialysis patients.

TitleCost-effectiveness of adjuvanted versus nonadjuvanted influenza vaccine in adult hemodialysis patients.
Publication TypeJournal Article
Year of Publication2011
AuthorsLee BY, Stalter RM, Bacon KM, H Y Tai J, Bailey RR, Zimmer SM, Wagner MM
JournalAm J Kidney Dis
Volume57
Issue5
Pagination724-32
Date Published2011 May
ISSN1523-6838
KeywordsAdjuvants, Immunologic, Adult, Aged, Cost-Benefit Analysis, Decision Trees, Female, Humans, Influenza Vaccines, Influenza, Human, Kidney Failure, Chronic, Male, Middle Aged, Renal Dialysis
Abstract

BACKGROUND: Currently more than 340,000 individuals are receiving long-term hemodialysis (HD) therapy for end-stage renal disease and therefore are particularly vulnerable to influenza, prone to more severe influenza outcomes, and less likely to achieve seroprotection from standard influenza vaccines. Influenza vaccine adjuvants, chemical or biologic compounds added to a vaccine to boost the elicited immunologic response, may help overcome this problem.STUDY DESIGN: Economic stochastic decision analytic simulation model.SETTING & PARTICIPANTS: US adult HD population.MODEL, PERSPECTIVE, & TIMEFRAME: The model simulated the decision to use either an adjuvanted or nonadjuvanted vaccine, assumed the societal perspective, and represented a single influenza season, or 1 year.INTERVENTION: Adjuvanted influenza vaccine at different adjuvant costs and efficacies. Sensitivity analyses explored the impact of varying influenza clinical attack rate, influenza hospitalization rate, and influenza-related mortality.OUTCOMES: Incremental cost-effectiveness ratio of adjuvanted influenza vaccine (vs nonadjuvanted) with effectiveness measured in quality-adjusted life-years.RESULTS: Adjuvanted influenza vaccine would be cost-effective (incremental cost-effectiveness ratio <$50,000/quality-adjusted life-year) at a $1 adjuvant cost (on top of the standard vaccine cost) when adjuvant efficacy (in overcoming the difference between influenza vaccine response in HD patients and healthy adults) ≥60% and economically dominant (provides both cost savings and health benefits) when the $1 adjuvant's efficacy is 100%. A $2 adjuvant would be cost-effective if adjuvant efficacy was 100%.LIMITATIONS: All models are simplifications of real life and cannot capture all possible factors and outcomes.CONCLUSIONS: Adjuvanted influenza vaccine with adjuvant cost ≤$2 could be a cost-effective strategy in a standard influenza season depending on the potency of the adjuvant.

DOI10.1053/j.ajkd.2010.12.016
Alternate JournalAm. J. Kidney Dis.
PubMed ID21396760
PubMed Central IDPMC3085888
Grant List5P01HK000086-02 / HK / PHITPO CDC HHS / United States
5R01LM009132-03 / LM / NLM NIH HHS / United States
5U54GM088491-02 / GM / NIGMS NIH HHS / United States
R01 LM009132 / LM / NLM NIH HHS / United States
R01 LM009132-04 / LM / NLM NIH HHS / United States
U54 GM088491 / GM / NIGMS NIH HHS / United States
U54 GM088491-02 / GM / NIGMS NIH HHS / United States
Publication Categories: